1Alpha,25-dihydroxyvitamin D3 decreases DNA binding of nuclear factor-kappaB in human fibroblasts.

FEBS Lett

Department of Cellular and Molecular Biology, Novartis Research Institute, Vienna, Austria.

Published: October 1998

AI Article Synopsis

Article Abstract

1Alpha,25-dihydroxyvitamin D3 (1,25-(OH)2-D3), the active metabolite of vitamin D, can inhibit NF-kappaB activity in human MRC-5 fibroblasts, targeting DNA binding of NF-kappaB but not translocation of its subunits p50 and p65. The partial inhibition of NF-kappaB DNA binding by 1,25-(OH)2-D3 is dependent on de novo protein synthesis, suggesting that 1,25-(OH)2-D3 may regulate expression of cellular factors which contribute to reduced DNA binding of NF-kappaB. Although NF-kappaB binding is decreased by 1,25-(OH)2-D3 in MRC-5 cells, IL-8 and IL-6 mRNA levels are only moderately downregulated, demonstrating that inhibition of NF-kappaB DNA binding alone is not sufficient for optimal downregulation of these genes.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0014-5793(98)01153-3DOI Listing

Publication Analysis

Top Keywords

dna binding
20
binding nf-kappab
8
inhibition nf-kappab
8
nf-kappab dna
8
binding
6
nf-kappab
6
dna
5
1alpha25-dihydroxyvitamin decreases
4
decreases dna
4
binding nuclear
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!